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doi:10.1016/j.jtcvs.2007.09.002bjectives: Despite pacemaker therapy in children and adolescents favoring
nitial epicardial approach, predictors of lead failure have not been well cla
he aim of this study was to assess the long-term outcomes and to de
redictors affecting lead durability in pediatric pacing therapy.
ethods: We reviewed the outcomes of 109 consecutive pacing leads implant
5 patients (median age, 5.2 years; range, 31 days–15.8 years), including 38
nd 71 ventricular leads. They consisted of 58 (53%) fishhooks, 37 (34%) sc
eads, and 14 (13%) steroid-eluting suture-on leads. Seventy (64%) were imp
n patients with structural heart disease.
esults: The leads were followed for a median of 6.4 years (range, 3 day
ears). Lead failure occurred in 29 leads (27%; median of 8.4 years after 
ation). Exit block or elevation of pacing threshold was the most common c
 18), but failures did not directly cause patient death. The overall 1-, 5-, 1
5-year lead survivals were 100%, 89.0%, 72.5%, and 55.5%, respectively. M
ariate Cox analysis revealed concurrent structural heart disease (relative risk, 
5% confidence interval, 1.27– 6.42; P  .011) to be the only significant predic
f lead failure.
onclusions: Epicardial leads provide a reliable technique for managing rhyth
isturbance problems in the pediatric population. The only significant predict
ead failure is the presence of structural heart disease.
 
he majority of children undergoing pacing therapy require long-term p
throughout their lives. In addition to the more frequent need for pace
generator changes because of high pacing rates and high stimulation ou
requent lead failure will lead to significant morbidity and mortality at the 
ystem replacement or at other times if lead failure is sudden and unexpecte
heoretic electronic durability of pacemaker generators is calculated on the ba
easurements of battery voltage and impedance or can be estimated readi
eans of past pacing history.1 In contrast, lead survival, either of epicardial
ndocardial leads, is not exactly predictable. Especially in a pediatric popul
picardial leads are all the more unpredictable in their durability because 
eveloping body size of young patients or characteristic childhood behaviors,
s creeping in babyhood and vigorous activity in early childhood. Henc
athered as much data relevant to lead durability or survival as possible. Few 
ave examined predictors affecting lead longevity in pediatric epicardial p
eads. Here we report our data on lead survival and examine predictors affecti
urability from more than 20 years’ experience in epicardial pacing therapy.
aterials and Methods
his retrospective study represents our experience in permanent pacemaker therapy
onsecutive epicardial leads in pediatric patients (age 16 years at lead implantation) 
ocial Insurance Chukyo Hospital. After approval of the institutional review board, pacing
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Deads were identified by serial number, and the following data were
btained from the pacemaker implantation registry and the data-
ase: lead type (fishhook, screw-in, or suture-on lead), pacing
hamber (atrium or ventricle), measured values at implantation
pacing threshold, sensing amplitude, impedance, and slew rate),
uration of use, and mode of failure. The following characteristics
f patients undergoing implantation were also obtained: electro-
hysiologic indications for permanent pacemaker therapy, age at
ead implantation, sex, structural congenital cardiac disease (S-
HD), prior cardiac operation or operations, and age at reimplan-
ation. The minimum energy threshold was calculated by using the
reviously derived energy formula as follows:
MET (J) Voltage (V)
2 Pulse width (ms) 106
Impedance () 1000 ms ⁄ s
ead failures were defined as lead replacement or a discontinua-
ion of pacing for any reason, including lead fracture, exit block,
xcessively elevated pacing threshold, sensing abnormalities, mus-
le stimulation, or infection.
One hundred nine epicardial pacing leads in 55 patients were
dentified from the database. Of these, 30 were male and 25 were
emale, and the median patient age at lead implantation was 5.2
ears (range, 31 days–15.8 years). The indications for permanent
acing therapy included atrioventricular block in 41 (75%), sinus
ode dysfunction in 11 (20%), and chronic atrial fibrillation with
ow ventricular rate in 3 (5%). Thirty-four (62%) of 55 patients had
nderlying S-CHD (Table 1). Among the 41 patients with 
entricular block, 19 had postoperative surgical block. One patient
ad no S-CHD but had subsequent myocarditis. Dual-chamber
acing (ventricular pacing with atrial synchronization or atrioven-
ricular synchronized pacing mode [DDD]) was used in 36 (65%)
Abbreviations and Acronyms
S-CHD structural congenital cardiac disease
able 1. Structural congenital heart disease
esion No. (%)
etralogy of Fallot 7 (21)
orrected TGA 5 (15)
eterotaxia 5 (15)
omplete AVSD 4 (12)
ransposition of great arteries 3 (9)
entricular septal defect 3 (9)
trial septal defect 2 (6)
ongenital mitral insufficiency 1 (3)
ouble-outlet right ventricle 1 (3)
ricuspid atresia 1 (3)
SD, CoA 1 (3)
solated hypoplastic right ventricle 1 (3)
otal 34 (100)
GA, Transposition of great arteries; AVSD, atrioventricular septal defect;
SD, ventricular septal defect; CoA, coarctation of the aorta.
S
62 The Journal of Thoracic and Cardiovascular Surgery ● Febratients. In the remaining 19, we used ventricular demand pacing
VVI) or rate-responsive VVI mode (VVIR).
Three types of epicardial leads were primarily used over the
0-year study period. Of 109 total leads implanted, 58 (53%) were
edtronic 4951 epicardial fishhook leads (Medtronic Inc, Minne-
polis, Minn), 37 (34%) were Medtronic 6917 or 5071 epicardial
crew-in leads, and 14 (13%) were Medtronic 4965 steroid-eluting
picardial suture-on leads (Table 2). The measured values a
ime of lead implantation are presented in Table 3.
The lead measurements are expressed as means  standard
eviation, and other data are expressed as medians with ranges.
ifferences between the 2 groups were analyzed by using the
tudent unpaired t test for means of continuous variables and the
2 test or Fisher exact probability test for categorical variables.
ead survival was calculated by using the Kaplan–Meier method
hen the data were stratified by lead type, pacing chamber, pres-
nce of concurrent S-CHD, and patient’s age at lead implantation.
ifferences between or among the subgroups were verified by
sing a log-rank test. Cox regression analysis was used to deter-
ine predictors of lead failure. Univariate predictors of events
ith P values of less than .10 were entered into a multivariate Cox
roportional hazards model by using a forward selection
lgorithm.
esults
here were 854 lead-years for the study period, with a
edian follow-up interval of 6.4 years (range, 3 days–22.9
ears). Complete follow-up data were obtained for all leads.
ive leads were censored because of 3 (5%) early deaths,
hich occurred at 3, 31, and 79 days after pacemaker
mplantation. These patients died because of severe heart
ailure in the context of an S-CHD. Pacemaker or lead
ysfunction was not implicated in any of the 3 cases.
nother lead was censored for elective lead change to an
ndocardial system at the time of battery depletion at 13.9
able 2. Lead characteristics
eads No. (%) Position (A/V) Type Steroid
edtronic 4951 58 (53) 33/25 Fishhook No
edtronic 5071 27 (25) 0/27 Screw-in No
edtronic 4965
Capsure
14 (13) 5/9 Suture-on Yes
edtronic 6917 AT 10 (9) 0/10 Screw-in No
otal 109 (100) 38/71
, Atrium; V, ventricle.
able 3. Implant measurements
easurements Atrial Ventricular P value
inimum energy
threshold (microJ)
1.8  2.9 1.6 2.3 .631
ensing amplitude (mV) 4.4 4.2 12.0 6.0 .001
mpedance () 408  142 542 179 .001
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Dears after implantation. Twenty-nine (27%) of 109 leads
ad to be replaced or abandoned at a median of 8.4 years
range, 1.4–18.8 years) after implantation, resulting in an
ncidence of 3.4% per lead per year of follow-up. Exit block
r elevation of stimulation threshold was found in 18 leads,
aking it the most prevalent cause of lead complication,
ollowed by lead fracture in 6, sensing problems in 2,
nfection in 2, and lead dislodgement in 1 (Table 4). O
9 failed leads, 20 were implanted in patients who had
tructural congenital heart disease, including 11 for surgical
lock.
Exit block or elevated pacing threshold occurred at a
edian of 6.2 years (range, 1.4–18.3 years) after implanta-
ion, including 6 atrial and 12 ventricular leads. It occurred
t an equal incidence in atrial and ventricular leads. Most of
hem (17/18, 94%) were non–steroid-eluting leads, and 14
14/18, 78%) were fishhook leads. Only 1 steroid-eluting
ead complicated exit block 3.3 years after implantation in a
atient with heterotaxia who had undergone repeated sur-
ical interventions. Lead fractures were encountered in 6
eads at a median of 12.1 years (range, 4.2–18.8 years) after
mplantation. All fractured leads except 1 (5/6, 83%) had
een implanted in the patients with surgical block through a
edian sternotomy approach. Sensing problems were inci-
entally discovered on a routine Holter electrocardiographic
ecording, including one oversensing and one undersens-
ng. A pair of atrial and ventricular leads implanted in a
ale patient with atopic dermatitis were infected with
ethicillin-resistant Staphylococcus aureus. Skin erosion of
he superficial pacemaker pocket was first noted 9.0 years
fter implantation and finally extended to mediastinitis,
ecessitating a rethoracotomy and removal of the entire
acemaker system. The patient was successfully treated
ith a new transvenous pacemaker implantation. Lead dis-
odgement occurred in 1 steroid-eluting lead, which had
een implanted by means of suturing on the epicardium.
The overall 1-, 5-, 10-, and 15-year freedoms from lead
ailure were 100%, 89.0%, 72.5%, and 55.5%, respectively
Figure 1). No differences were noted among the lead t
here the 5-year freedoms from lead failure were 91.3% for
shhook, 87.5% for screw-in, and 84.4% for steroid eluting
able 4. Failed-lead characteristics
ause No. (%) Position (A/V)
xit block 18 (62) 6/12
ead fracture 6 (21) 2/4
ensing problem 2 (7) 0/2
nfection 2 (7) 1/1
ead dislodgement 1 (3) 0/1
otal 29 (100) 9/20
, Atrium; V, ventricle; F, fishhook; S-in, suture-in lead; S-on, suture-on leuture-on leads, respectively. When the leads were com- c
The Journal of Thoracice
,
ared based on steroid elution, the 5-year freedom from lead
ailure was 89.9% for non–steroid-eluting leads, showing no
ignificant difference from the above data for steroid-eluting
eads (Figure 2). Neither the pacing chamber nor the
ient’s age at lead implantation affected lead failure rates.
he only significant difference was noted in the lead failure
ates among those with concurrent S-CHD. The leads were
ore likely to survive in patients without S-CHD than in
hose with S-CHD (P  .008). The freedoms from lead
ailure at 1, 5, 10, and 15 years were, respectively, 100%,
3.5%, 79.0%, and 74.6% in the former group and 100%,
6.2%, 66.1%, and 31.4% in the latter (Figure 3).
Table 5 shows the relative risks of possible predictor
ead failure evaluated by means of univariate Cox regres-
ion analysis. In the 11 variables the implanted lead mea-
urements (minimum energy threshold, sensing amplitude,
mpedance, and slew rate) were examined within each sub-
roup of atrial and ventricular leads, respectively. Univari-
te analysis detected S-CHD, sex, and prior cardiac surgery
s significant predictors (P  .05) and age at lead implan-
ation as of borderline significance (P  .077). Subsequent







-CHD, structural congenital heart disease. *P  .05.
igure 1. Kaplan–Meier freedom from lead failure in overall epi-
ardial leads.
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D ultivariate analysis with a stepwise forward Cox propor-
ional hazards model confirming the presence of S-CHD
as the only significant predictor of lead failure (relative
isk, 2.85; 95% confidence interval, 1.27–6.42; P  .011).
iscussion
picardial leads have been reported to have only short-term
urability and show a high rate of lead failure. Therefore the
ndocardial approach has gained favor in general us2-5
evertheless, the epicardial approach for pacemaker ther-
igure 2. Kaplan–Meier freedom from lead failure for non–ste-
oid-eluting (solid line) versus steroid-eluting (broken line) epi-
ardial leads. NS, Not significant.
igure 3. Kaplan–Meier freedom from lead failure in patients
ith (broken line) or without (solid line) structural congenitalweart disease. S-CHD, Structural congenital heart disease.
64 The Journal of Thoracic and Cardiovascular Surgery ● Febrpy continues to be required. Some children and young
dults evidence relative or absolute contraindications to the
ransvenous approach because of small body size, presence
f a right-to-left shunt, or absence of venous access caused
y congenital anomalies or surgical interventions.6 Other
hildren might be able to benefit from either an endocardial
r epicardial system. Endocardial leads, however, might
omplicate venous thrombosis, vascular obstruction, or
trioventricular valve integrity.7-11 There are potential con-
erns about disproportion of lead length caused by somatic
rowth or difficulty in cases of lead extraction.12-14 Because
he majority of children undergoing pacing therapy will
equire pacing for life, they are commonly exposed to such
isks for a nearly normal lifespan. Therefore, although it is
echnically feasible to implant endocardial leads in children,
e apply the epicardial approach. Our policy in practicing
ermanent pacemaker therapy in a pediatric population has
een that epicardial pacing takes precedence in principle for
ll patients weighing less than 30 kg or those 16 years of age
r younger.
We found that lead failures occurred in 29 leads, 27% of
ll implanted epicardial leads during a median of 6.4 years,
nd the lead failure rate determined by means of Kaplan–
eier analysis was found to be 89.0% and 72.5% at 5 and
0 years, respectively. These observations are consistent
able 5. Univariate Cox regression analysis on epicardial
ead durability
ariables RR 95% CI
P
value
ge at lead implantation (y) 0.91 0.82–1.01 .077
emale sex 0.40 0.17–0.94 .036
tructural congenital heart disease 2.85 1.27–6.42 .011
rior cardiac surgery 2.28 1.01–5.16 .047
acing chamber (atrial, 0; ventricular, 1) 1.18 0.53–2.62 .688
ead type
Fishhook (vs suture-on) 0.73 0.15–3.42 .697
Screw-in (vs suture-on) 0.31 0.05–1.80 .191
teroid elution 1.66 0.35–7.85 .519
inimum energy threshold
Atrial (microJ) 0.95 0.68–1.32 .753
Ventricular (microJ) 1.07 0.92–1.21 .423
ensing amplitude
Atrial (mV) 1.08 0.97–1.20 .173
Ventricular (mV) 1.06 0.99–1.13 .105
mpedance
Atrial () 1.00 1.00–1.01 .662
Ventricular () 1.00 1.00–1.00 .115
lew rate
Atrial (ms/s) 0.83 0.15–4.65 .828
Ventricular (ms/s) 1.35 0.81–2.25 .255
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Dohen and colleagues15 reported the incidence of epicardi
ead failure observed in 16% of leads for a median
ollow-up interval of 2.4 years, whereas Thomson and as-
ociates16 reported it in 34% for a median of 2.3 years. In
uch studies various probabilities of lead survival rate were
eported in a variety of cohorts, ranging from 58% to 91%
t 5 years and 30% to 72% at 10 years.12,15-18 Walker and
oworkers19 reported an excellent outcome of epicard
eads implanted in an adult population with S-CHD, show-
ng 92% survival at 5 years and 84% at 10 years. This wide
pectrum of lead survival rates among the study groups
ighlights the fact that the epicardial cardiac pacing is
omplex and that the performance of the leads might not be
he sole reason for their high failure rate in the context of
omplicated patient characteristics. The survival rate in
dults suggests that epicardial leads might have superior
otential for their durability in children as well.
In this study the presence of concurrent S-CHD was
dentified as predictive of subsequent lead failure. The
aplan–Meier analysis showed that the leads implanted in
atients with S-CHD had a significantly higher failure rate
han that of those implanted in patients without S-CHD. In
ultivariate Cox proportional hazards analysis, S-CHD was
evealed to be the only significant predictor affecting lead
urvival. The leads implanted in the patients with S-CHD
ad 2.9 times higher risk for lead failure compared with
hose implanted in patients without S-CHD. Cohen and
olleagues15 reported no relationship between lead durab-
ty and S-CHD, whereas in the same study they mentioned
he possibility that S-CHD and cardiac surgery affect long-
erm pacing thresholds and that increased pacing thresholds
re associated with reduced lead longevity.2,3
Scar tissue, fat, fibrosis, or myocardial degeneration can
ffect the pacing threshold. We speculate that there might be
number of unquantifiable factors that could increase the
isks of lead failure in the epicardium and myocardium,
here the leads were implanted in such patients with
-CHD.
We, however, have dismissed steroid elution, lead posi-
ion, patient age at lead implantation, or measurement val-
es of implanted leads as predictors for lead complications.
any recent reports have mentioned the enhanced effect of
teroid-eluting epicardial leads. Beaufort-Krol and cowork-
rs20 reported their performance, including longevity, to 
ery similar to those of conventional endocardial leads.
homson and associates16 found a 76% survival of stero
luting epicardial leads at 5 years, and Cohen and col-
eagues15 reported an 83% survival at 5 years. Beder 
oworkers21 reported an opposite hazard that both early 
ate precipitous lead failures were still occurring in steroid-
luting leads, despite their superior electrical performances.
n this report we have a rather small number of steroid-
luting leads with a relatively short observation period, and
The Journal of Thoracichey were not shown to improve lead survival. Their use
bviously means a lower pacing threshold and less drain on
atteries and thus longer battery life, not to mention less
ubsequent surgical intervention.22
The primary goal of permanent pacemaker therapy is
table pacing with minimum patient risk and avoidance of
omplications for their lifespan. The present study of epi-
ardial leads over a 20-year period among Japanese patients
onfirmed that satisfactory lead durability could be achieved
hrough careful observation and meticulous management.
ur experience, as well as the excellent results of Walker
nd coworkers,19 encourages us to keep offering epicard
acing to particular patients. We should consider the feasi-
ility not only of early performance but also of how best to
chieve a lifetime of successful, uninterrupted pacing. We
elieve that our experiences described here might be helpful
n the understanding of how to pace this population.
This is a retrospective analysis over a long observation
eriod. Choice of lead has varied among surgeons, with
echnical development over time. The relatively small num-
er of leads limits statistical power, and further accumula-
ion of experiences is required.
We thank Nobuyuki Hamajima, MD, MPH, PhD, from the
epartment of Preventive Medicine/Biostatistics and Medical De-
ision Making, Nagoya University Graduate School of Medicine,
or his kind statistical review. We also thank Masami Nagashima,
D, and Masaki Matsushima, MD, from the Department of Pe-
iatric Cardiology for patient management and follow-up.
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